Serum Institute has applied for full market authorisation of Covishield: CEO Adar Poonawala

NEW DELHI: Serum Institute has applied to the Indian health ministry and Central Drugs Standard Control Organisation (CDSCO) for full market authorisation for Covishield vaccine, company's CEO Adar Poonawalla informed in a tweet on Friday.
Serum Institute, which produces AstraZeneca's Covid-19 vaccine under the brand name Covishield, has supplied more than 1.25 billion doses of the vaccine in India.
"Supplies of the Covishield vaccine in India, have exceeded 1.25 billion doses; the government of India now has enough data for full market authorisation", he said.

Serum Institute, which is also the world's biggest vaccine maker, was granted approval for emergency use of Covishield in India at the beginning of the year.
(With inputs from agencies)